---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-011676"
form_type: "8-K"
ticker: "ZIVO"
cik: "0001101026"
company_name: "Zivo Bioscience, Inc."
filed_at: "2022-08-23T23:59:59+00:00"
generated_at: "2026-06-23T21:53:50.735220+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zivo Bioscience receives USDA CVB jurisdiction for coccidiosis biologic; new study in Sept 2022

## Summary
- USDA CVB affirms jurisdiction over novel immune-modulating biologic for coccidiosis in broilers, removing regulatory ambiguity.
- Company continues licensing discussions with a major animal health company for product candidate.
- Strategic partner to begin 42-day in vivo study in September 2022; results expected Q1 2023.
- No financial results or guidance were provided in this corporate update.

## SEC filing metadata
- accession: 0001654954-22-011676
- form_type: 8-K
- ticker: ZIVO
- cik: 0001101026
- company_name: Zivo Bioscience, Inc.
- filed_at: 2022-08-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1101026/000165495422011676/0001654954-22-011676-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1101026/000165495422011676/zivo_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-011676
- JSON: https://secwatch.observer/filing/0001654954-22-011676.json
- Plain text: https://secwatch.observer/filing/0001654954-22-011676.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.